Fed. Circ. Backs Ban On Generic Treximet
The Federal Circuit on Friday upheld an injunction barring three generic-drug makers from offering their own versions of Pozen Inc.'s migraine treatment Treximet, rejecting arguments that the patents for the drug...To view the full article, register now.
Already a subscriber? Click here to view full article